Genprex, Inc. (GNPX): Nasdaq/NYSE listing notice — Genprex receives Nasdaq deficiency notices for bid price and equity requirements

Genprex, Inc.

Nasdaq notified Genprex on Feb 7, 2025 that its stock closed below $1.00 for 30 consecutive business days, non-compliant with Rule 5550(a)(2).
Company has 180 days, until Aug 6, 2025, to regain compliance by having bid price at $1.00+ for 10 consecutive days.
On Feb 11, 2025, Staff granted extension for prior stockholders' equity deficiency; must report $2.5M equity by Q1 2025 10-Q filing due May 15, 2025.
Company faces risk of delisting if it fails to meet either requirement; can appeal but no assurance of success.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid pric

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nas

View on SEC.gov

Browse all listing & compliance notices →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-003490

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.